Biotechnology company BioSenic’s affiliate Medsenic has amended its licence agreement with Australia-based pharmaceutical company Phebra for the oral formulation of arsenic trioxide (OATO).
SYDNEY and BOURNE END, England, Nov. 3, 2021 /PRNewswire/ -- Leading Australian pharmaceutical group Phebra Holdings ('Phebra') is pleased to announce that it has completed a share purchase agreement with the UK hospital specialty pharmaceutical company Flexipharm Austrading Limited ('FAL').
Phebra Establishes New Subsidiary In Canada And Announces Marketing Approval
Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with Better. Critical Care Medicines, today announced the commercial availability in the UK of its differentiated arsenic trioxide injection product, Arsenic Trioxide Phebra, following the successful grant of a Marketing Authorisation by the MHRA.
Australian pharmaceutical firm, Phebra, has announced a collaboration and licensing agreement with the University of Wollongong (UOW) to continue development of newly patented arsenic compounds that potentially treat haematologic malignancies and solid tumours.
Phebra Expands Lane Cove West Head Office
Phebra Launches New Brand Of Phosphate Tablets
Australian pharma Phebra has set up operations in the UK with the establishment of a new wholly-owned subsidiary company.